Liwen Zhou

Liwen Zhou

Auto-generated profile, based on publicly available information

Liwen Zhou

Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2023 in Nature Cancer
Verified
Journal Article
Open access
PDF file
YWYuanzhong Wu
Yuanzhong Wu
LZLiwen Zhou
Liwen Zhou
YZYezi Zou
Yezi Zou
YZYijun Zhang
Yijun Zhang
MZMeifang Zhang
Meifang Zhang
TKTiebang Kang
Tiebang Kang
Immunotherapies targeting the PD-1/PD-L1 axis have become first-line treatments in multiple cancers. However, only a limited subset of individuals achieves durable benefits because of the elusive mechanisms regulating PD-1/PD-L1. Here, we report that in cells exposed to interferon-γ (IFNγ), KAT8 undergoes phase separation with induced IRF1 and forms biomolecular condensates to upregulate PD-L1. Multivalency from both the specific and promiscuous interactions between IRF1 and KAT8 is required for condensate formation. KAT8–IRF1 condensation promotes IRF1 K78 acetylation and binding to the CD247 (PD-L1) promoter and further enriches the transcription apparatus to promote transcription of PD-L1 mRNA. Based on the mechanism of KAT8–IRF1 condensate formation, we identified the 2142–R8 blocking peptide, which disrupts KAT8–IRF1 condensate formation and consequently inhibits PD-L1 expression and enhances antitumor immunity in vitro and in vivo. Our findings reveal a key role of KAT8–IRF1 condensates in PD-L1 regulation and provide a competitive peptide to enhance antitumor immune responses.

1 August 2012 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
JDJingchun Du
Jingchun Du
LZLiwen Zhou
Liwen Zhou
XCXiaoyong Chen
Xiaoyong Chen
SYSunxing Yan
Sunxing Yan
MKMing Ke
Ming Ke
AXAndy Peng Xiang
Andy Peng Xiang

24 May 2016 in Cell Discovery
Verified
Journal Article
Open access
YWYuanzhong Wu
Yuanzhong Wu
LZLiwen Zhou
Liwen Zhou
XWXin Wang
Xin Wang
JLJinping Lu
Jinping Lu
RZRuhua Zhang
Ruhua Zhang
TKTiebang Kang
Tiebang Kang
The regulation of stability is particularly crucial for unstable proteins in cells. However, a convenient and unbiased method of identifying regulators of protein stability remains to be developed. Recently, a genome-scale CRISPR-Cas9 library has been established as a genetic tool to mediate loss-of-function screening. Here, we developed a protein stability regulators screening assay (Pro-SRSA) by combining the whole-genome CRISPR-Cas9 library with a dual-fluorescence-based protein stability reporter and high-throughput sequencing to screen for regulators of protein stability. Using Cdc25A as an example, Cul4B-DDB1DCAF8 was identified as a new E3 ligase for Cdc25A. Moreover, the acetylation of Cdc25A at lysine 150, which was acetylated by p300/CBP and deacetylated by HDAC3, prevented the ubiquitin-mediated degradation of Cdc25A by the proteasome. This is the first study to report that acetylation, as a novel posttranslational modification, modulates Cdc25A stability, and we suggest that this unbiased CRISPR-Cas9 screening method at the genome scale may be widely used to globally identify regulators of protein stability.

17 July 2025 in Science
Verified
Journal Article
Closed access
LZLiwen Zhou
Liwen Zhou
ZCZhenxuan Chen
Zhenxuan Chen
YZYezi Zou
Yezi Zou
XZXia Zhang
Xia Zhang
ZWZifeng Wang
Zifeng Wang
TKTiebang Kang
Tiebang Kang
The maintenance of histone H3 lysine 9 trimethylation (H3K9me3) involves the recognition of preexisting modifications by heterochromatin protein 1 (HP1), which recruits the methyltransferase suppressor of variegation 3-9 homolog 1 (SUV39H1) to methylate the adjacent newly incorporated histones, establishing a positive feedback loop. However, how this positive feedback is restricted to maintain H3K9me3 homeostasis remains largely unknown. We performed an unbiased genome-scale CRISPR-Cas9 screen and identified CUL5 ASB7 E3 ubiquitin ligase as a negative regulator of H3K9me3. ASB7 is recruited to heterochromatin by HP1 and promotes SUV39H1 degradation. During mitosis, cyclin-dependent kinase 1 (CDK1) phosphorylates ASB7, preventing its interaction with SUV39H1, leading to SUV39H1 stabilization and H3K9me3 restoration. Our findings reveal a dynamic circuit involving HP1, SUV39H1, and ASB7 that governs H3K9me3 homeostasis, ensuring faithful epigenetic inheritance and preventing excessive heterochromatin formation.

16 July 2026 in Nature Cancer
Verified
Journal Article
Open access
YWYuanzhong Wu
Yuanzhong Wu
LZLiwen Zhou
Liwen Zhou
YZYezi Zou
Yezi Zou
YZYijun Zhang
Yijun Zhang
MZMeifang Zhang
Meifang Zhang
TKTiebang Kang
Tiebang Kang